Searle, Skokie, IL, has developed an interactive corporate Web site. The site includes The Pipeline Game allows players to develop a new drug and take it all the way through market clearance.
Searle, Skokie, IL, has developed an interactive corporate Web site. The site includes The Pipeline Game allows players to develop a new drug and take it all the way through market clearance.
The game begins with the players choosing a medical condition to target. The players develop a lead compound and proceed through various stages of clinical development, including discovery synthesis, chemical synthesis scale-up, and stability and formulation.
The players then move into the safety and testing phases of drug development. When the testing phases are complete, the player submits a New Drug Application to the Food and Drug Administration for marketing consideration.
The players decisions can prove successful or they may have to return to the beginning and choose a new lead compound.
In addition to The Pipeline Game, Searle has included other informational tools such as Healthcare Solutions, which focuses on their three therapeutic areas, arthritis, cardiovascular disease and women's health. In each category, Searle highlights key issues regarding treatment trends, incidence statistics and new research.
Searle's The Pipeline Game and information tools can be found on their World Wide Web site at http://www.searlehealthnet.com. PR
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
March 14th 2025New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.